Fractional CFO

Aphios Corporation•North Reading, MA

2d•Hybrid

About The Position

Aphios Corporation is a clinical-stage biotechnology company advancing differentiated nanotechnology platforms and next-generation therapeutics across oncology, neurodegenerative disease, infectious disease, and substance-use disorder. As the company enters its next phase of growth and capital-markets readiness, Aphios is seeking an experienced Part-Time / Fractional Chief Financial Officer (CFO) with direct biotech IPO and public-company preparation experience to work closely with the CEO and Board. This role is designed for a senior biotech finance executive who has successfully guided companies through IPO preparation, public-company readiness, and alternative public-market pathways, and who is interested in a high-impact, flexible leadership engagement rather than a full-time operating role.

Requirements

Bachelor's degree in Finance, Accounting, or related field(MBA, CPA, or CFA strongly preferred)
10-15+ years of senior financial leadership experience in biotechnology or life sciences
Demonstrated experience taking a biotech company through IPO or IPO readiness
Strong working knowledge of SEC reporting, GAAP, internal controls, and audit processes
Experience with venture-backed, clinical-stage, or R D-intensive organizations
Familiarity with PIPEs, crossover investors, and public-market capital strategy
Executive presence with the ability to engage effectively at the Board and investor level
Comfortable operating in lean, entrepreneurial environments

Nice To Haves

Responsibilities

Lead financial strategy, capital planning, and cash-flow management for a growth-stage biotech
Prepare the company for IPO and public-company readiness, including internal controls, reporting infrastructure, and governance
Oversee GAAP-compliant financial reporting, audit readiness, and risk management
Develop and maintain long-range financial models aligned with clinical, regulatory, and commercialization milestones
Support investor relations, Board communications, and external stakeholder engagement
Structure and evaluate PIPE financings, crossover fund participation, and late-stage private capital strategies
Advise on NASDAQ and NYSE uplisting requirements and readiness timelines
Evaluate SPAC or de-SPAC-adjacent opportunities, as appropriate, without over-engineering the business
Interface with investment banks, auditors, securities counsel, and regulatory advisors
Oversee grant accounting and compliance (e.g., NIH, SBIR/STTR)